TABLE I.

Effect of methylation status of methylguanine DNA methyltransferase (mgmt) promoter on progression-free survival (pfs) and overall survival (os) in patients receiving radiotherapy plus temozolomide (tmz) versus radiotherapy (RT) alone^a

Clinical endpoint	TMZ + RT (n=106)	RT (n=100)
Methylated MGMT (n)	46	46
6-Month PFS	47.8	68.9
2-Year OS	22.7	46.0
Unmethylated MGMT (n)	54	60
6-Month PFS	35.2	40.0
2-Year OS	<2	13.8

^aAdapted from reference ³².